Home Blog Page 519

Ubiqconn Technology Showcases Mission-Critical Satellite Connectivity Solutions at SATShow Week 2026

Demonstrating integrated Satcom innovations across land, sea, and air with rugged computing, AI-enabled systems, and resilient communications

WASHINGTON, March 16, 2026 /PRNewswire/ — Ubiqconn Technology, a leading provider of industrial Internet of Vehicles (IoV) and embedded Internet of Things (IoT) solutions, will showcase its latest satellite-enabled connectivity technologies at SATShow Week 2026, taking place March 23–26 in Washington, D.C. Visitors can explore Ubiqconn Technology’s innovations at Booth #2747.

Ubiqconn Technology Showcases Mission-Critical Satellite Connectivity Solutions at SATShow Week 2026
Ubiqconn Technology Showcases Mission-Critical Satellite Connectivity Solutions at SATShow Week 2026

Under the theme “Ubiquitous Connectivity: Integrating Satcom Across Land, Sea, and Air,” Ubiqconn Technology will demonstrate mission-critical solutions that combine rugged computing, AI-powered systems, and Iridium satellite communications to enable resilient connectivity in remote and demanding environments.

For maritime environments, Ubiqconn Technology will also present the Marlin GMDSS system and SGA110 Mobile Gateway, combining weather intelligence, vessel tracking, and dependable VoIP and satellite communications to enhance situational awareness and ensure reliable communications for offshore, ocean-going, and emergency marine operations.

RuggON Corp., a subsidiary of Ubiqconn Technology and a leading provider of rugged mobile computing solutions, will present a range of mission-critical platforms at the show.

A key highlight is the SPARK 7 Ground Control System (GCS), an advanced controller for unmanned platforms integrating AI-driven autonomous navigation and real-time image analysis. Designed for aerial and unmanned operations, the system enables precise command, control, and mission coordination across a wide range of defense, government, and remote operational scenarios.

Supporting land-based deployments, RuggON will also showcase its rugged computing platforms, including the SOL 7 rugged tablet and VORTEX 07X vehicle-mounted computer, both equipped with Iridium satellite capabilities to deliver dependable data transmission and operational visibility in harsh terrestrial environments.

“Reliable satcom infrastructure is increasingly essential for organizations operating in remote and mission-critical environments,” said Paul Hsieh, CEO of Ubiqconn Technology. “Our focus is on delivering ruggedized, reliable, and resilient platforms that support continuous communications and operational readiness across land, sea, and air.”

About Ubiqconn Technology

Ubiqconn Technology is a leading provider of rugged mobile and satellite connectivity solutions, delivering value-added services across critical sectors including satellite communication, maritime, rugged smart mobility, and government. Guided by the vision of “Ubiquitous Connectivity,” Ubiqconn Technology emphasizes user-centric thinking, agile go-to-market strategies, and engineering excellence to help clients solve real-world challenges and bring innovation to life. Its subsidiary, RuggON Corp., designs and manufactures rugged mobile computing devices for industrial and mission-critical environments.

For more information, please visit our website: www.ubiqconn.com and www.ruggon.com.

Celltrion announces U.S. availability of AVTOZMA® (tocilizumab-anoh) subcutaneous (SC) formulation

  • AVTOZMA® (tocilizumab-anoh) is among the first wave of tocilizumab biosimilars with both intravenous (IV) and subcutaneous (SC) formulations approved and commercially available in the United States
  • The launch of AVTOZMA SC further diversifies Celltrion’s immunology portfolio beyond TNF-alpha and IL-12/23 inhibitors providing a broader range of treatment solutions for immune-mediated inflammatory diseases

INCHEON, South Korea, March 16, 2026 /PRNewswire/ — Celltrion, Inc. today announced that AVTOZMA® (tocilizumab-anoh) subcutaneous (SC) formulation is now commercially available to patients in the United States.

With this launch, Celltrion’s AVTOZMA becomes one of the first tocilizumab biosimilars to have both an intravenous (IV) and a SC formulation approved by the U.S. Food and Drug Administration (FDA) and available on the U.S. market.

“The introduction of AVTOZMA SC is a pivotal moment for Celltrion, underscoring our dedication to delivering effective, accessible and user-friendly therapies for patients with chronic inflammatory diseases,” said Thomas Nusbickel, Chief Commercial Officer of Celltrion USA. “By offering both IV and SC formulations, we aim to provide patients and healthcare professionals with greater flexibility in treatment decisions, while continuing to broaden our immunology portfolio with therapies that address diverse inflammatory pathways.”

The SC formulation of AVTOZMA is indicated for the treatment of rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (PJIA) and systemic juvenile idiopathic arthritis (SJIA). AVTOZMA SC is available in a 162 mg/0.9 mL solution for injection in a single-dose prefilled syringe or a single-dose prefilled autoinjector, allowing patients the flexibility and convenience of administering their treatment at home. [1]

Celltrion provides support to U.S. patients prescribed AVTOZMA through its patient support program, Celltrion CONNECT™. Celltrion CONNECT™ offers tailored support to its patients and caregivers with a full range of services including injection training, reimbursement assistance and educational resources to patients and healthcare professionals.

Notes to Editors:

About AVTOZMA® (CT-P47, tocilizumab-anoh)
AVTOZMA® (tocilizumab-anoh), containing the active ingredient tocilizumab, is a recombinant humanized monoclonal antibody that acts as an interleukin 6 (IL-6) receptor antagonist. Based on data from the global Phase III clinical trial designed to evaluate the efficacy, pharmacokinetics (PK), safety, and immunogenicity of CT-P47 compared to reference tocilizumab, AVTOZMA received approval from the U.S. Food and Drug Administration (FDA) and European Commission (EC) in January and February 2025, respectively. In July 2025, the FDA approved an additional indication for the intravenous (IV) formulation of AVTOZMA for the treatment of cytokine release syndrome (CRS) in adult and pediatric patients aged two years and older.

INDICATION 

AVTOZMA® (tocilizumab-anoh) IV is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of:

  • Rheumatoid Arthritis (RA): Adult patients with moderately to severely active RA who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
  • Giant Cell Arteritis (GCA): Adult patients with GCA.
  • Polyarticular Juvenile Idiopathic Arthritis (pJIA): Patients 2+ years-old with active pJIA.
  • Systemic Juvenile Idiopathic Arthritis (sJIA): Patients 2+ years-old with active sJIA.
  • Cytokine Release Syndrome (CRS): Adults and pediatric patients 2+ years-old with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome
  • COVID-19: Hospitalized adult patients with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

AVTOZMA® (tocilizumab-anoh) SC is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of:

  • Rheumatoid Arthritis (RA): Adult patients with moderately to severely active RA who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
  • Giant Cell Arteritis (GCA): Adult patients with GCA.
  • Polyarticular Juvenile Idiopathic Arthritis (pJIA): Patients 2+ years-old with active pJIA.
  • Systemic Juvenile Idiopathic Arthritis (sJIA): Patients 2+ years-old with active sJIA.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF SERIOUS INFECTIONS

AVTOZMA® and other tocilizumab products may increase the risk of serious infections, potentially leading to hospitalization or death, especially in patients using concurrent immunosuppressants.

If a serious infection develops, interrupt AVTOZMA until the infection is controlled. Reported infections include:

  • Active tuberculosis (TB) which may present with pulmonary or extrapulmonary disease. Test for latent TB before and during treatment (except in COVID-19 patients) and treat latent infections before starting AVTOZMA.
  • Invasive fungal infections: Such as candidiasis, aspergillosis, and pneumocystis, may present as disseminated rather than localized disease.
  • Opportunistic infections, including bacterial, viral and other opportunistic pathogens.

Monitor patients for signs of infection, including TB, during and after AVTOZMA treatment.
Contraindications: Known hypersensitivity to tocilizumab products.
Serious Infections. Serious and sometimes fatal infections have been reported with AVTOZMA. Do not use during active infections, including localized infections. Discontinue AVTOZMA if a serious infection occurs and resume only once controlled.

Gastrointestinal (GI) Perforation. Gastrointestinal perforations, often linked to diverticulitis, have been reported with tocilizumab. Use AVTOZMA cautiously in high-risk patients and promptly evaluate new abdominal symptoms for early detection and management.

Hepatoxicity. Monitor for hepatic injury signs. Avoid AVTOZMA if ALT/ AST >1.5x ULN (RA/GCA) or >10x ULN (COVID-19); discontinue if ALT/AST >5x ULN or symptoms of liver disease develop.

Changes in Laboratory Parameters. Monitor neutrophils, platelets, liver enzymes, and lipids due to potential treatment-related changes; avoid initiating AVTOZMA in patients with critically low ANC or platelet counts.

Immunosuppression. The impact of AVTOZMA on malignancy development is unknown, but it may increase risk as an immunosuppressant.

Hypersensitivity Reactions, including anaphylaxis, and death, have occurred; administer IV infusions with anaphylaxis management support, discontinue permanently if reactions occur, and avoid use in patients with known hypersensitivity.

Demyelinating Disorders. The impact of tocilizumab on demyelinating disorders is unknown, but rare cases were reported; monitor symptoms and use caution with preexisting or recent disorders.

Active Hepatic Disease and Hepatic Impairment. Treatment with AVTOZMA is not recommended.

Live Vaccines. Avoid concurrent use with AVTOZMA.

Adverse Reactions (≥5%) include upper respiratory tract infections, nasopharyngitis, headache, hypertension, elevated ALT, and injection site reactions.

For more information, see Full Prescribing Information.

About Celltrion

Celltrion is a leading biopharmaceutical company that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people’s lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world’s first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. For more information, please visit our website www.celltrion.com/en-us and stay updated with our latest news and events on our social media – LinkedInInstagramX, and Facebook.

About Celltrion USA

Celltrion USA is Celltrion’s U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to innovative biologics to improve care for U.S. patients. Celltrion’s FDA-approved biosimilar products in immunology, oncology, hematology, and endocrinology include: INFLECTRA® (infliximab-dyyb), TRUXIMA® (rituximab-abbs), HERZUMA® (trastuzumab-pkrb), VEGZELMA® (bevacizumab-adcd), YUFLYMA®(adalimumab-aaty), AVTOZMA® (tocilizumab-anho), STEQEYMA® (Ustekinumab-stba) STOBOCLO® (denosumab-bmwo), OSENVELT® (denosumab-bmwo), and OMLYCLO® (omalizumab-igec), as well as the novel biologic ZYMFENTRA® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion’s unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information, please visit www.celltrionusa.com and stay updated with our latest news and events on our social media – LinkedIn.

FORWARD-LOOKING STATEMENT

Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws. This press release contains forward looking statements. These statements may be also identified by words such as “prepares”, “hopes to”, “upcoming”, “plans to”, “aims to”, “to be launched”, “is preparing”, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, “anticipates”, the negative of these words or such other variations thereon or comparable terminology.

In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Inc. and its subsidiaries’ management, of which many are beyond its control.

Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties associated with the company’s business, including the risk factors disclosed in its Annual Report and/or Quarterly Reports, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such statements.

Celltrion Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.

Trademarks

AVTOZMA® is a registered trademark of Celltrion Inc.
ACTEMRA® is a registered trademark of Chugai Pharmaceutical Co., Ltd. 

References

[1] AVTOZMA U.S. prescribing information (2025)

For further information please contact: 
Brendi Bluitt
bbluitt@jpa.com  
+1 202-545-7722

 

Air Premia Expands Economy Seat Pitch by Reducing Seat Count

  • Economy seat pitch on aircraft HL8701 increased from 31 to 33 inches
  • Total seat count adjusted from 344 to 326 as part of cabin space and comfort upgrades, including new carpet installation

SEOUL, South Korea, March 16, 2026 /PRNewswire/ — Air Premia, Korea’s only hybrid airline, has enhanced passenger comfort by reducing the total number of seats while expanding seat pitch to enhance passenger comfort.

Air Premia Expands Economy Seat Pitch by Reducing Seat Count
Air Premia Expands Economy Seat Pitch by Reducing Seat Count

The airline announced that the economy class seat pitch on aircraft HL8701 has been increased from 31 inches to 33 inches. Following the adjustment, the aircraft’s total seat capacity has been reduced from 344 seats to 326 seats, a decrease of 18 seats.

Unlike the common industry practice of increasing seat density to improve profitability, Air Premia has focused on expanding seat space to improve passenger comfort and overall travel experience.

The aircraft completed its seat reconfiguration in mid-March and entered service on March 16. Passengers on flights operated by this aircraft will now experience the expanded seat pitch.

Air Premia has been continuously improving seat space to enhance comfort for passengers traveling on long-haul routes. In 2024, the airline also reconfigured two aircraft previously operating with 338 seats, reducing them to 320 seats while expanding economy class seat pitch.

The airline is currently carrying out sequential seat adjustments on aircraft configured with 344 seats, with plans to expand the economy class seat pitch on all aircraft to 33 inches or more within this year.

Air Premia currently operates a fleet of nine aircraft, configured with 309 seats (three aircraft), 320 seats (two aircraft), 326 seats (two aircraft), and 344 seats (two aircraft). All aircraft except the 344-seat configuration currently operate with an economy class seat pitch of 33 inches or greater.

Along with the seat pitch expansion, Air Premia has also replaced the cabin carpet. The newly installed carpet is produced using digital printing technology, allowing the airline’s brand identity to be naturally incorporated into the cabin interior design.

In addition, the new carpet is lighter than the previous version, contributing to aircraft weight reduction and supporting environmental benefits such as improved fuel efficiency.

“Air Premia is committed to continuously improving seat space and the cabin environment so that passengers traveling on long-haul routes can enjoy a more comfortable journey,” an Air Premia official said. “We will continue to introduce various service enhancements to further elevate the customer experience.”

TOYO to Participate in the 38th Annual ROTH Investor Conference

TOKYO, March 16, 2026 /PRNewswire/ —  TOYO Co., Ltd (Nasdaq: TOYO) (OTC: TOYWF),  (“TOYO” or the “Company”), a solar solution company, today announced that it will participate in the 38th Annual ROTH Conference, taking place on March 22-24, 2026 at The Ritz Carlton in Dana Point, California.

TOYO management will participate in one-on-one meetings with institutional investors during the conference.

Attendance at the conference is by invitation only for ROTH clients. Interested investors should contact their ROTH sales representative to schedule a meeting.

About TOYO Co., Ltd.

TOYO is a solar company committed to becoming a full-service provider of solar solutions provider in the global market, integrating upstream production of wafers and silicon, midstream production of solar cells, downstream production of photovoltaic modules, and potentially other stages of the solar power supply chain. TOYO is well-positioned to produce high-quality solar cells at a competitive scale and cost.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “look forward to,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the section entitled “Risk Factors” in TOYO’s annual report on Form 20-F, as well as discussions of potential risks, uncertainties, and other important factors in TOYO’s subsequent filings with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof. TOYO specifically disclaims any obligation to update any forward-looking statement, whether due to new information, future events, or otherwise. Readers should not rely upon the information on this page as current or accurate after its publication date.

Contact Information:

For TOYO Co., Ltd
IR@toyo-solar.com

Crocker Coulson
Email: crocker.coulson@aummedia.org
Tel: (646) 652-7185

Alar Announced Buprenorphine Injectable, ALA-1000, Demonstrated Long-Term Efficacy and Favorable Safety Profile in Canine Osteoarthritis Pain Management

  • A study in client-owned dogs with osteoarthritis demonstrated that a single injection of ALA-1000 effectively mitigates pain and improves functional mobility, with a sustained drug release profile for at least 1 month. The study also confirmed a favorable safety profile with repeated use, particularly within the geriatric population.

TAICHUNG, March 16, 2026 /PRNewswire/ — Alar Pharmaceuticals Inc. (Alar, TPEx:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs), announces the completion and positive results of ALA-1000 study in client-owned dogs with osteoarthritis. The results demonstrate the efficacy, safety, tolerability, and pharmacokinetic (PK) durability for ALA-1000, a subcutaneous buprenorphine LAI, at target dose in dogs with osteoarthritis-associated pain.

The primary endpoint was based on the owner-rated Canine Brief Pain Inventory (CBPI) questionnaire, which evaluates pain severity, its impact on dogs’ daily mobility, and overall quality of life. Secondary endpoint included veterinarian-assessed lameness scoring for evaluating lameness, pain on manipulation, range of motion, and joint swelling. The study results revealed that a single injection of ALA-1000 produced a remarkably high treatment success rate (≥75%) at Day 28 across dogs with varying baseline pain severity, as assessed by either CBPI or lameness scoring. Treatment success was defined as a ≥1-point reduction in pain severity score and ≥2-point reduction in pain interference score on the CBPI, or a ≥1-point reduction in lameness or ≥2-point reduction in total score on the lameness scoring. Moreover, in dogs receiving continuous monthly dosing of ALA-1000 for more than 1 year, no evidence of tolerance was observed based on efficacy assessments.

ALA-1000 demonstrated a well-tolerated safety profile at target dose, particularly within the geriatric dog population. No drug-related injection site reactions, including redness, swelling, or irritation were observed given the minimal injection volume.

PK data demonstrated that ALA-1000 exhibited a well-controlled release profile with no evidence of initial burst or dose dumping. Low but therapeutically effective buprenorphine plasma levels were maintained for at least one month following single injection. In addition, no significant dose accumulation was observed after repeated monthly dosing, supporting its suitability for long-term pain management.

The new animal drug application of ALA-1000 has been submitted in Taiwan and granted priority review, which should help speed up the approval timeline.

“With its well-controlled buprenorphine release profile and favorable safety results, ALA-1000 presents strong potential for expansion into additional pain indications, such as cancer pain and postoperative pain.” said Yung-Shun Wen, CEO of Alar Pharmaceuticals.

“ALA-1000 represents a breakthrough in veterinary pain management.” said Charles Lin, Founder and Chairman of Alar Pharmaceuticals, “We firmly believe that ALA-1000 creates a triple-win solution for pets, pet owners, and veterinarians by delivering effective and safe pain control, offering a convenient dosing regimen that reduces the burden of daily administration or frequent clinic visits, and enabling veterinarians to ensure proper administration and timely follow-up care.”

About ALA-1000

ALA-1000 is the first and only long-acting opioid analgesic providing 1-month to 3-month buprenorphine exposure designed for veterinary use. Buprenorphine has been widely investigated and used in veterinary medicine since 1980s. As evidenced by a study in dogs with osteoarthritis, ALA-1000 provides meaningful benefits by offering long-lasting pain relief, improving functional mobility, and enhancing quality of life.

NOTICE: This news release contains specific forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the Company’s product development plans, study outcomes, potential therapeutic benefits, regulatory approval processes, and commercial strategy. All forward-looking statements are based on management’s current expectations and beliefs only as of the date of this news release and, in addition to the assumptions specifically mentioned in the above paragraphs, there are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. Alar disclaims any intention or obligation to update publicly or revise such statements, whether as a result of new information, future events or otherwise.

For more information, please visit Alar’s website at https://alarpharm.com/

CLEAR AND ORACLE RED BULL RACING TAKE ON ‘HELMET HAIR’ DURING FORMULA ONE SHANGHAI GRAND PRIX

Performance Under Pressure: From Extreme Cockpit Conditions to Everyday Pressure, CLEAR Brings Breakthrough Scalp Science to Fans

SHANGHAI, March 16, 2026 /PRNewswire/ — In Formula One racing, performance is defined by precision, focus and the ability to deliver under extreme pressure. CLEAR, the world’s No.1 men’s shampoo and Haircare Partner of Oracle Red Bull Racing, applies that same mindset to developing high-performance scalp and haircare solutions. As the excitement of motorsport returned to Shanghai this weekend, CLEAR is showcasing how a CLEAR™ HEAD can be the performance edge when focus is everything, from the intensity under the helmet to high-pressure moments in everyday life.

CLEAR and Oracle Red Bull Racing take on ‘helmet hair’ during formula one shanghai grand prix
CLEAR and Oracle Red Bull Racing take on ‘helmet hair’ during formula one shanghai grand prix

Racing at speeds over 300 km/h, Formula One drivers endure some of the toughest physical conditions in sport. Inside the cockpit, temperatures can reach 60°C, while drivers can lose up to 3 L of fluid during a single race. With heart rates soaring and forces reaching 4–6G in corners, hours under a helmet create one of racing’s most overlooked realities: helmet hair.  Helmet hair moments have become a viral fan favourite across social media, even as drivers have acknowledged the heat, sweat, itch and distractions that come with it.

CLEAR is helping turn helmet hair from something people try to avoid into a symbol of performance under pressure. Engineered for extreme conditions, the new CLEAR Men Scalp MaxCharge Shampoo has been extreme-tested to fight 10x scalp problems such as dandruff, grease and weak roots, plus its 1.82s fast-action formula delivers 10x energised scalp defence with up to 72-hour freshness. By tackling scalp stressors at the root, CLEAR helps remove distractions for clarity and confidence both on and off track.

CLEAR Men Scalp MaxCharge Shampoo
CLEAR Men Scalp MaxCharge Shampoo

CLEAR redefines helmet hair as a symbol of performance under pressure
CLEAR redefines helmet hair as a symbol of performance under pressure

“At CLEAR, we engineer scalp care products for people who expect the very best from themselves every day,” said Mohamed Elsharkawy, Unilever China’s Hair Care Marketing Director and Global Vice President of CLEAR. “Our partnership with Oracle Red Bull Racing allows us to bring that innovation to life and connect with fans who share the same ambition to maximise their potential.”

Visitor experienced the new CLEAR Men Scalp MaxCharge Shampoo
Visitor experienced the new CLEAR Men Scalp MaxCharge Shampoo

Throughout the Shanghai race weekend, the CLEAR x Oracle Red Bull Racing partnership came to life through a series of fan activations and appearances across the city and trackside.

CLEAR x Oracle Red Bull Racing Fan Experience
From 13–17 March, in North Bund Bay (500 East Daming Road), fans stepped into a barbershop-inspired activation blending performance grooming with the world of Formula One racing. Visitors experienced the new CLEAR Men Scalp MaxCharge Shampoo and explored Oracle Red Bull Racing’s newly designed RB22, all within a bold, spatial environment of immersive interactivity designed to recreate the pressure, precision, and unstoppable performance of CLEAR x Oracle Red Bull Racing. More information:

  • RB22 Showcase – CLEAR brought Oracle Red Bull Racing’s newly designed RB22 from London all the way to the Bund in Shanghai, displayed alongside authentic racing suits and helmets for fans to experience up close.
  • Skyline Projection – CLEAR illuminated the Shanghai skyline with a mixed-reality projection across Citi Group Tower, bringing the CLEAR x Oracle Red Bull Racing collaboration to life in one of the city’s most iconic locations.
  • Interactive Racing Challenges – Visitors tested their skills through interactive challenges including an Oracle Red Bull Racing simulator and driver reaction tests inspired by the demands of Formula One racing.
  • Performance Grooming Barbershop – A one-stop barbershop experience featured high-performance scalp treatments using CLEAR Men Scalp MaxCharge Shampoo, as well as styling and grooming by celebrity hairstylist Shangqiao Zhen.

CLEAR brought Oracle Red Bull Racing’s newly designed RB22 to Shanghai
CLEAR brought Oracle Red Bull Racing’s newly designed RB22 to Shanghai

CLEAR barbershop-inspired activation in North Bund Bay Shanghai
CLEAR barbershop-inspired activation in North Bund Bay Shanghai

From the intense demands of Formula One racing to the pressures of daily life, CLEAR believes that performance starts with a CLEAR™ HEAD, and when distractions are eliminated, every opportunity can be maximised. By bringing its scalp science into the world of elite motorsport, the brand is redefining helmet hair into a symbol of performance under pressure. CLEAR Men Scalp MaxCharge  Shampoo is available at retailers and online.

ABOUT CLEAR: 

CLEAR is the No.1 men’s hair care shampoo globally and sold in 60+ markets around the world. Backed by over 50 years of dermatology-led scalp science and research with 30,000 consumers, CLEAR is recognized as a leading scalp expert brand helping people worldwide KEEP A CLEAR™ HEAD.

For more information about CLEAR, please visit www.clearhaircare.com.

ABOUT ORACLE RED BULL RACING: 

Since its inception, Oracle Red Bull Racing has been a major force in the FIA Formula 1 World Championship, the globe’s premier motorsport category. Founded in 2005 to expand parent company Red Bull’s presence in professional motor racing and to disrupt the status quo within the sport through a bold mix of passion, playfulness, ambition and achievement, Oracle Red Bull Racing has grown to become one of F1’s most successful teams. With multiple Constructors’ and Drivers’ world titles and more than 100 race wins to its credit, Oracle Red Bull Racing continues its pursuit of ultimate performance – as a race team, as a home of champions and as an innovator operating at the cutting edge of technology.

ABOUT UNILEVER: 

Unilever is one of the world’s leading suppliers of Beauty & Wellbeing, Personal Care, Home Care, and Foods products, with sales in over 190 countries and products used by 3.7 billion people every day. We generated sales of €50.5 billion in 2025. 

For more information about Unilever and our brands, please visit www.unilever.com.  

 

DITP Positions Thailand as Asia’s Content Hub at Thai Night Hong Kong 2026, Highlighting Four Strategic Pillars and the Global Rise of Y and GL Series


HONG KONG SAR – Media OutReach Newswire – 16 March 2026 – The Department of International Trade Promotion (DITP), Ministry of Commerce, Royal Thai Government, continues to promote Thailand’s content and entertainment industry in international markets. This initiative is carried out through business networking activities at “Thai Night Hong Kong 2026”, alongside Thailand’s participation in the Hong Kong International Film & TV Market (FILMART) 2026, one of Asia’s most prominent marketplaces for film and television content.

DITP Positions Thailand as Asia’s Content Hub at Thai Night Hong Kong 2026, Highlighting Four Strategic Pillars and the Global Rise of Y and GL Series

FILMART 2026 will take place from 17–20 March 2026 at the Hong Kong Convention and Exhibition Centre (HKCEC) in the Hong Kong Special Administrative Region of the People’s Republic of China. The event provides an opportunity for Thai content companies to connect with international buyers, investors, and industry partners while showcasing the strengths of Thailand’s entertainment industry on the global stage.

Ms. Sunanta Kangvalkulkij, Director-General of the Department of International Trade Promotion (DITP), stated that the department places strong emphasis on supporting Thailand’s content and entertainment industry in international markets. DITP aims to help Thai entrepreneurs expand business opportunities and strengthen partnerships with global industry players, while enhancing the competitiveness of Thai companies in the global marketplace.

“Thailand’s participation in FILMART and the organization of Thai Night Hong Kong 2026 provide an important platform to present the capabilities of Thai content companies and to foster new partnerships with international producers, distributors, and investors. These activities will help expand business opportunities and further promote Thai content in global markets,” she said.

At FILMART 2026, Thailand will showcase the strengths of its entertainment industry through four strategic pillars: Talents, Locations, Production, and Post-production. These pillars highlight Thailand’s skilled creative professionals, diverse filming locations, internationally recognized production standards, and advanced post-production capabilities, including visual effects and animation, supported by government measures that help facilitate international investment.

At the same time, DITP continues to capitalize on the growing global popularity of Y and GL series, one of the fastest-growing segments of Thailand’s entertainment industry, with valued at more than THB 4.9 billion in 2025. These genres have gained strong international fan bases and present significant opportunities for Thai content to reach global audiences.

Thailand is also encouraging the development of new content formats such as short-form dramas, which are increasingly popular on digital platforms and streaming services. These formats allow Thai creators to expand their presence across global distribution channels and reach wider international audiences.

With the remarkable growth and international recognition of Thailand’s entertainment industry in recent years—driven by talented filmmakers, diverse filming locations, and high production standards—Thai Night Hong Kong 2026 aims to move beyond showcasing industry capabilities toward fostering concrete international business collaboration.

A key highlight of the event will be the creation of a strategic platform for partnership discussions between Thai entrepreneurs and international industry partners. The event is expected to welcome more than 500 global investors, producers, directors, and media representatives, providing opportunities to expand business partnerships and further strengthen Thailand’s presence in the global entertainment industry.

For more information and updates about Thai Night Hong Kong 2026 and Thailand’s participation in FILMART 2026, please visit:
www.ditp.go.th
www.facebook.com/thailandfilms

Hashtag: #DITP

The issuer is solely responsible for the content of this announcement.

GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth

Group Performance

  • Revenue: US$959.5 million, +61.4% year-on-year
  • Gross profit: US$553.2 million, +103.3% year-on-year
  • Adjusted net profit: US$230.3 million, +285.0% year-on-year

Business Units’ Performance

  • GenScript Life Science Group (LSG): US$522.1 million, +14.8% year-on-year
  • ProBio: US$388.7 million, +309.1% year-on-year
  • Bestzyme: US$58.0 million, +7.9% year-on-year

PISCATAWAY, N.J., March 16, 2026 /PRNewswire/ —

GenScript Biotech Corporation continues to scale platform synergies, global reach, and automation-enabled operations, with revenue reaching US$959.5 million (+61.4% YoY); adjusted net profit rising up to US$230.3 million.
GenScript Biotech Corporation continues to scale platform synergies, global reach, and automation-enabled operations, with revenue reaching US$959.5 million (+61.4% YoY); adjusted net profit rising up to US$230.3 million.

GenScript Biotech Corporation (HKEX: 1548), a global company providing life science research services and products, biologics development & manufacturing services, and industrial biotechnology innovation, today announced financial results for full year 2025.

“2025 was a year of accelerated growth and disciplined execution for GenScript,” said Sherry Shao, Rotating CEO of GenScript Biotech Corporation. “We delivered strong results while continuing to strengthen the integrated capabilities that differentiate GenScript – from gene synthesis and protein engineering to biologics development and industrial biotechnology innovation. Our performance reflects both solid end-market demand and the benefits of a more connected, globally-scaled operating model.”

“Looking ahead, GenScript is well positioned to benefit from the next wave of biotechnology innovation, including AI-enabled discovery, advanced therapeutics, and rising demand for globally-reliable research and manufacturing infrastructure. We remain focused on high-quality growth, operational discipline, and long-term value creation for customers and shareholders.”

FY2025 Financial Highlights*

Revenue

In 2025, GenScript recorded revenue of approximately US$959.5 million, representing an increase of 61.4% from approximately US$594.5 million in 2024. The growth is primarily attributable to (i) substantial increase of license revenue, mainly derived from LaNova sublicensing, (ii) continuous investment in commercial efforts, combined with global brand transformation, and enhanced brand awareness, particularly in Europe and North America, (iii) growing industry demand for AI-driven drug development, and multi-antibody drug development, fueling growth in gene-to-protein businesses, (iv) harnessing rebound in biologics CDMO demand and capitalizing on recovering market conditions, (v) continuous market expansion supported by launch of innovative industrial enzyme products.

Gross Profit

Group’s gross profit increased by 103.3% to approximately US$553.2 million from approximately US$272.1 million in 2024 – primarily attributable to revenue expansion, especially license revenue, in biologics development services. Adjusted gross profit increased by 98.6% over the prior period.

Selling and Distribution Expenses

Selling and distribution expenses increased by 12.9% to approximately US$99.5 million, from approximately US$88.1 million in 2024 – attributable to the (i) expansion of commercial teams and local recruitment of experienced professionals, (ii) continued investment in regional operations, supporting business development and customer engagement in key global markets. Adjusted selling and distribution expenses increased by 14.6% over the prior period.

Administrative Expenses

Administrative expenses increased by 12.4% to approximately US$128.6 million in 2025 from approximately US$114.4 million in 2024 – mainly attributable to (i) continued expenditures in capacity expansion infrastructure and enhanced administrative functions (ii) initial phase expenses for the new site. Adjusted administrative expenses increased by 14.8% over the prior period.

R&D Expenses

R&D expenses increased by 32.4% to approximately US$71.2 million from approximately US$53.8 million in 2024 – mainly attributable to the accelerated recruitment of highly-skilled professionals and expansion of strategic research initiatives. Adjusted R&D expenses increased by 32.8% over the prior period.

Adjusted Net Profit

Adjusted net profit of the Group was approximately US$230.3 million for FY2025.

Strategic Drivers of FY2025 Performance

1. Integrated platform synergies
The Group continued to capture greater value from integration across its technology platforms. LSG’s gene-to-protein workflow became an increasingly important growth engine, with platform synergies contributing approximately 65% of LSG’s 2025 revenue growth.

2. Global reach and diversified revenue base
GenScript further strengthened its international footprint, growing across NA, EU, and APAC. Europe delivered five consecutive years of growth, with 2025 revenue increasing 29% year-on-year, while Asia-Pacific grew 33% year-on-year, underscoring broader geographic diversification.

3. Product and technology innovation
GenScript continued to advance proprietary technologies and product platforms spanning life science research tools, biologics discovery and development, and industrial biotechnology applications. These innovations strengthened differentiation, improved productivity, and supported customer adoption across high-growth applications.

4. Automation and digitalization
Expanded use of automation and AI-enabled systems in R&D and manufacturing, improved efficiency, shortened timelines, and enhanced operational resilience. Within 2025, four major production sites of LSG are upgraded into automated, AI-driven “lights-out” facilities, and 60% of global production capacity will be powered by AI-driven automation by end-2026.

Business Segment Highlights

GenScript Life Science Group
GenScript LSG generated US$522.1 million in revenue, up 14.8% year-on-year, surpassing the US$500 million milestone. The business continued to benefit from adoption of its integrated gene-to-protein platform, strong demand from pharma and biotech customers, and growing traction in AI-enabled discovery.

Among key highlights:

  • Revenue from integrated protein expression services grew +50%.
  • Orders flowing from gene synthesis into integrated protein expression platform increased +160% year-on-year.
  • Serving 66,000+ active customers globally and cited in 118,000+ publications, reinforcing its position as a trusted, global scientific community partner.

ProBio
ProBio delivered exceptional growth in 2025, with revenue reaching US$388.7 million, up 309.1% year-on-year. Excluding one-time items, fee-for-service revenue grew 21% year-on-year, with improving order momentum. ProBio secured 41 antibody & protein drug development projects; 60 cell and gene therapy CDMO projects and 20 new IND clearances across CGT programs.

Expanding its discovery, CMC, and GMP manufacturing capabilities, ProBio strengthened its position with international customers and advanced flexible collaboration models – including fee-for-service, co-development, and out-licensing.

Bestzyme
Bestzyme generated US$58.0 million revenue, up 7.9% year-on-year. The business continued advancing industrial biotechnology innovation through new enzyme products, stronger AI-enabled R&D capabilities, and international market development.

Performance highlights include increased contribution from innovative enzyme products, progress in sweet protein commercialization, and 140% improvement in R&D efficiency driven by AI-powered workflows.

A Resilient Global Operating Network: Automation, Worldwide Operations, ESG
GenScript continued to reinforce its global operating network to support long-term, high-quality growth. In 2025, the Group advanced its manufacturing footprint across NA, EU, and APAC, with increasing use of automation and digitalization to improve productivity, speed, and reliability. GenScript’s global operating model is designed to support stronger service consistency, greater supply resilience, and scalable execution across its businesses.

ESG Leadership and Responsible Growth
GenScript strengthened its ESG profile, being recognized by leading external benchmarks:

  • MSCI ESG Rating upgraded to AA
  • Included in the FTSE4Good Index Series
  • Awarded EcoVadis Silver Medal
  • Included in the S&P Sustainability Yearbook

These recognitions reflect GenScript’s ongoing commitment to responsible growth, operational integrity, and long-term stakeholder value-creation.

Outlook

Looking ahead to 2026, GenScript expects continued growth supported by rising demand for integrated biotechnology platforms, advanced therapeutics development, and higher productivity from automation and digitalized operations.

The Group’s business focus remains on:

  • strengthening cross-platform synergy
  • broadening global customer reach
  • improving leverage through automation and digitalization
  • advancing proprietary technologies across biologics and industrial biotechnology

Based on current trends and management guidance, GenScript expects:

  • 15%–18% revenue growth for GenScript LSG
  • 20%–25% fee-for-service revenue growth for ProBio
  • 10%–15% revenue growth for Bestzyme

About GenScript Biotech Corporation

Founded in 2002 in New Jersey, GenScript Biotech Corporation operates through three core businesses; GenScript Life Science Group, ProBio, and Bestzyme. The Group accelerates innovation in biotech & healthcare by providing researchers and companies with the building blocks needed to develop groundbreaking treatments and products. Guided by its mission to ‘Make People and Nature Healthier Through Biotechnology’, GenScript supports customers across the full innovation lifecycle (biotechnology research, drug discovery, biologics development, and industrial biotechnology applications) with a team of 5,700+ employees serving 200,000+ customers across 100+ countries.

Investor & Media Contacts

Investor Relations: ir@genscript.com
Media Inquiries:
melis.inceer@genscript.com
Company Website:
https://www.genscript.com

FINANCIAL REVIEW

2025

2024

Change

US$’000

US$’000

US$’000

Continuing operations

Revenue

959,526

594,486

365,040

Gross profit

553,204

272,125

281,079

Loss after income tax expense

(532,404)

(173,774)

(358,630)

Adjusted net profit

230,345

59,826

170,519

Discontinued operation

Loss for the period from Legend Group, net of tax

(203,149)

203,149

Gain on deconsolidation of Legend Group, net of tax

3,232,210

(3,232,210)

(Loss)/Profit for the year

(532,404)

2,855,287

(3,387,691)

(Loss)/Profit attributable to owners of the Company

(532,830)

2,961,877

(3,494,707)

(Loss)/Earnings per share for the year (US cent)

-Basic

(24.58)

139.63

(164.21)

-Diluted

(24.58)

135.97

(160.55)

Adjusted profit and expenses:

Gross profit

556,576

280,320

276,256

Selling and distribution expenses

95,963

83,731

12,232

Administrative expenses

122,668

106,883

15,785

R&D expenses

69,237

52,123

17,114

*To better reflect the key performance of the Group’s current operations, adjusted net profit is calculated by excluding the impact of the following items:
(i) share-based compensation expenses;
(ii) the impact of acquisitions and fair value losses on preferred shares;
(iii) losses from foreign exchange forward and option contracts;
(iv) impairment losses on long-term assets;
(v) foreign exchange gains or losses;
(vi) fair value gains or losses on non-current financial assets;
(vii) unrealized financing costs related to equity financing activities;
(viii) share of losses from Legend Biotech and service fees related to deconsolidation; and
(ix) impairment of investments in Legend Biotech.

This document is intended to provide a summary overview and does not constitute a complete description of the Company, its securities, or related matters. For more detailed information, please refer to the official announcement released by GenScript Group on March 15 on the Company’s website. All information is subject to the official announcement.